Marina Norberg has extensive experience as an approved auditor at PwC and as authorized accounting consultant within Aspia AB, the management team to which she belonged.
Marina Norberg will report to CEO Einar Pontén and be part of Lipum’s management team.
“I am very pleased to welcome Marina to Lipum. She brings long experience and qualified competence that will be of great benefit in the continued development of Lipum”, says CEO Einar Pontén.
For further information, please contact:
Einar Pontén, CEO
+46 70 5783495
Lipum is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.